3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)- manufacturers
|
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)- Basic information |
| Product Name: | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)- | | Synonyms: | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)-;PPDA-001 HCL SALT;ICEC0942 (CT7001);(3R,4R)-4-(((7-(Benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-yl)amino)methyl)piperidin-3-olhydrochloride;CT7001 hydrochloride;1), (3R,4R)-;3-Piperidinol, 4-3-(1-methylethyl)-7-(phenylmethyl)aminopyrazolo1,5-apyrimidin-5-ylaminomethyl-, hydrochloride (1;ICEC0942;ICE C0942;ICE-C0942;CT7001;CT-7001;CT 7001 | | CAS: | 1805789-54-1 | | MF: | C22H31ClN6O | | MW: | 430.98 | | EINECS: | | | Product Categories: | | | Mol File: | 1805789-54-1.mol | ![3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)- Structure](CAS/20211123/GIF/1805789-54-1.gif) |
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)- Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: Soluble | | form | A solid | | color | White to light yellow | | InChIKey | YMNPLAHCOLEZJE-ALSDZXMDNA-N | | SMILES | N(C1=CC(NC[C@H]2CCNC[C@@H]2O)=NC2=C(C(C)C)C=NN12)CC1C=CC=CC=1.Cl |&1:6,11,r| |
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)- Usage And Synthesis |
| Uses | CT7001 Hydrochloride, is a selective CDK7 inhibitor. | | in vivo | Samuraciclib (ICEC0942; 100 mg/kg; oral gavage; daily; for 14 days; female nu/nu-BALB/c athymic nude mice) treatment inhibits tumor growth by 60% at day 14, and is accompanied by highly significant reductions in PolII Ser2 and Ser5 phosphorylation in PBMCs and in tumors[1].
The combination of Samuraciclib (ICEC0942) and ICI 47699 treatment shows complete growth arrest of estrogen receptor (ER)-positive tumor xenografts[1]. | Animal Model: | Female nu/nu-BALB/c athymic nude mice (7-week old) with MCF7 cells[1] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; daily; for 14 days | | Result: | At day 14, tumor growth was inhibited by 60%.
|
| | IC 50 | CDK7: 41 nM (IC50); CDK2: 578 nM (IC50); CDK1: 1.8 μM (IC50); CDK4: 49 μM (IC50); CDK5: 9.4 μM (IC50); CDK6: 34 μM (IC50); CDK9: 1.2 μM (IC50) |
| | 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, hydrochloride (1:1), (3R,4R)- Preparation Products And Raw materials |
|